CRISPR Therapeutics（纳斯达克代码：CRSP）报告其季度每股亏损$(0.44)，优于分析师预期的$(1.13)，超出预期61.06%。与去年同期的每股收益$1.10相比，下降了140%。公司季度销售额为$35.691百万，超出分析师预期的$7.657百万，超出预期366.13%。与去年同期的销售额$201.206百万相比，下降了82.26%。
以上内容来自Benzinga Earnings专栏，原文如下：
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(1.13) by 61.06 percent. This is a 140 percent decrease over earnings of $1.10 per share from the same period last year. The company reported quarterly sales of $35.691 million which beat the analyst consensus estimate of $7.657 million by 366.13 percent. This is a 82.26 percent decrease over sales of $201.206 million the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.